Skip to main content
. 2016 Nov 8;291(53):26958–26969. doi: 10.1074/jbc.M116.735365

FIGURE 1.

FIGURE 1.

Calpain inhibitor III and calpastatin pretreatment attenuates IL-1β treatment-induced monolayer hyperpermeability and calpain activity. Calpain inhibitor III (A, n = 4; p < 0.05) and calpastatin (B, n = 4; p < 0.05) pretreatment attenuates IL-1β-induced monolayer hyperpermeability significantly. Knockdown of calpain-1 by siRNA attenuates IL-1β treatment-induced monolayer hyperpermeability (C, n = 4; p < 0.05). Monolayer permeability is expressed as a percentage control of FITC-dextran-10 kDa fluorescence intensity, plotted on y axis. Calpastatin and calpain inhibitor III pretreatment attenuates IL-1β treatment-induced calpain activity significantly (D, n = 4; p < 0.05). Calpain activity is expressed as RFU, plotted on the y axis. Data are expressed as mean ± % S.E. *a indicates significant increase compared with the control group; *b indicates significant decrease compared with the IL-1β treatment group.